"Graves Ophthalmopathy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.
| Descriptor ID |
D049970
|
| MeSH Number(s) |
C11.270.842 C11.675.349.500.500 C19.874.283.605.500 C19.874.397.370.500 C20.111.555.500
|
| Concept/Terms |
Graves Ophthalmopathy- Graves Ophthalmopathy
- Ophthalmopathy, Graves
- Ophthalmopathies, Thyroid-Associated
- Ophthalmopathies, Thyroid Associated
- Thyroid-Associated Ophthalmopathies
- Thyroid Associated Ophthalmopathies
- Thyroid-Associated Ophthalmopathy
- Thyroid Associated Ophthalmopathy
- Dysthyroid Ophthalmopathy
- Dysthyroid Ophthalmopathies
- Ophthalmopathies, Dysthyroid
- Ophthalmopathy, Dysthyroid
- Ophthalmopathy, Thyroid-Associated
- Ophthalmopathy, Thyroid Associated
Myopathic Ophthalmopathy- Myopathic Ophthalmopathy
- Myopathic Ophthalmopathies
- Ophthalmopathies, Myopathic
- Ophthalmopathy, Myopathic
Congestive Ophthalmopathy- Congestive Ophthalmopathy
- Congestive Ophthalmopathies
- Ophthalmopathies, Congestive
- Ophthalmopathy, Congestive
- Ophthalmopathy, Infiltrative
- Infiltrative Ophthalmopathies
- Infiltrative Ophthalmopathy
- Ophthalmopathies, Infiltrative
- Edematous Ophthalmopathy
- Edematous Ophthalmopathies
- Ophthalmopathies, Edematous
- Ophthalmopathy, Edematous
|
Below are MeSH descriptors whose meaning is more general than "Graves Ophthalmopathy".
Below are MeSH descriptors whose meaning is more specific than "Graves Ophthalmopathy".
This graph shows the total number of publications written about "Graves Ophthalmopathy" by people in this website by year, and whether "Graves Ophthalmopathy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Graves Ophthalmopathy" by people in Profiles.
-
Gupta A, Nobori A, Wang Y, Rootman D, Goldberg R. Lateral Rectus Muscle Expands More Than Medial Rectus Following Maximal Deep Balanced Orbital Decompression. Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr; 34(2):140-142.
-
Kleinberg TT, Bilyk JR. Evolution of Disc Edema in Thyroid-Related Compressive Optic Neuropathy. Ophthalmic Plast Reconstr Surg. 2016 Jul-Aug; 32(4):e100.
-
Zhang-Nunes SX, Dang S, Garneau HC, Hwang C, Isaacs D, Chang SH, Goldberg R. Characterization and outcomes of repeat orbital decompression for thyroid-associated orbitopathy. Orbit. 2015 Apr; 34(2):57-65.
-
Ayabe R, Rootman DB, Hwang CJ, Ben-Artzi A, Goldberg R. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014 Sep-Oct; 30(5):415-9.
-
Politi LS, Godi C, Cammarata G, Ambrosi A, Iadanza A, Lanzi R, Falini A, Bianchi Marzoli S. Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg. Eur Radiol. 2014 May; 24(5):1118-26.
-
Borodic GE, Hinkle DM. Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression". Ophthalmic Plast Reconstr Surg. 2013 May-Jun; 29(3):241.
-
Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg. 2011 Jul-Aug; 27(4):e87-8.
-
Madaschi S, Rossini A, Formenti I, Lampasona V, Marzoli SB, Cammarata G, Politi LS, Martinelli V, Bazzigaluppi E, Scavini M, Bosi E, Lanzi R. Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review. Endocr Pract. 2010 Jul-Aug; 16(4):677-85.